While the combination of dabrafenib and trametinib is recommended in the treatment of BRAF V600E-mutated NSCLC in the main guidelines, in the event of the appearance of a BRAFV600E mutation as a resistance mechanism after osimertinib progression, there is currently disagreement over the best course of action for concurrently addressing BRAF and EGFR in lung cancer. The gene discussed is BRAF; the disease is lung cancer.